Overexpression of Galectin-3 in Chronic Lymphocytic Leukemia Is Associated With 17p Deletion: A Short Report

被引：6

作者：

Michalova, Zuzana ^{[1
,2
,3
]}

Coma, Matus ^{[3
,4
]}

Kicova, Miroslava ^{[1
,2
,3
]}

Gabzdilova, Juliana ^{[5
,6
]}

Dedinska, Kinga ^{[5
,6
]}

Guman, Tomas ^{[5
,6
]}

Hajikova, Martina ^{[1
,2
,3
]}

Veselinyova, Dominika ^{[7
]}

Giertlova, Maria ^{[7
]}

Gal, Peter ^{[4
,8
,9
]}

Sarissky, Marek ^{[1
,2
,3
]}

机构：

[1] Safarik Univ, Fac Med, Dept Pharmacol, Cent Lab Clin Cytometry, Kosice, Slovakia

[2] Medirex As, Kosice, Slovakia

[3] Safarik Univ, Fac Med, Dept Pharmacol, Trieda SNP 1, Kosice, Slovakia

[4] East Slovak Inst Cardiovasc Dis Inc, Dept Biomed Res, Ondayska 8, Kosice 04011, Slovakia

[5] Safarik Univ, Louis Pasteur Univ Hosp, Dept Hematol & Oncohematol, Kosice, Slovakia

[6] Safarik Univ, Fac Med, Kosice, Slovakia

[7] Medirex As, Dept Clin Genet, Kosice, Slovakia

[8] Charles Univ Prague, Fac Med 3, Prague Burn Ctr, Prague, Czech Republic

[9] Safarik Univ, Lab Cell Interact, MediPk, Kosice, Slovakia

来源：

ANTICANCER RESEARCH | 2019年 / 39卷 / 06期

关键词：

Galectin-3; chronic lymphocytic leukemia; B-cells; flow cytometry; cytogenetics; 17p deletion; B-CELL LYMPHOMA; EXPRESSION; MOLECULES; WORKSHOP;

D O I：

10.21873/anticanres.13408

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background/Aim: Galectins belong to the family of galactose-binding proteins known to play an important role in the processes of cell proliferation, differentiation, migration and neoplastic progression. Herein, we studied the expression of galectin-3 (Gal-3) in chronic lymphocytic leukemia (CLL). Materials and Methods: The expression of Gal-3 was analyzed by means of multiparametric flow cytometry in normal and pathological B-cells from peripheral blood and bone marrow samples of 67 patients with CLL. Results: Pathological B-cells expressed significantly higher levels of cytoplasmic Gal-3 than normal B-cells. Moreover, overexpression of cytoplasmic Gal-3 was observed in the prognostically poorest subgroup of CLL patients, namely those with 17p deletion. Conclusion: Our results indicate a possible role of galectin-3 in CLL pathophysiology and its potential value as a prognostic marker and therapeutic target.

引用

页码：2805 / 2810

页数：6

共 50 条

[21] The clinical significance of chromosome 17p deletion in chronic lymphocytic leukemia: A study of 180 consecutive patients
Tam, C. S.
Wierda, W.
O'Brien, S. M.
Lerner, S.
Abruzzo, L. V.
Ferrajoli, A.
Kantarjian, H. M.
Keating, M. J.
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
[22] Chronic Lymphocytic Leukemia With Deletion 17p: Emerging Treatment Options THE STEPHENS/BYRD ARTICLE REVIEWED
Jain, Nitin
O'Brien, Susan
ONCOLOGY-NEW YORK, 2012, 26 (11): : 1067 - +
[23] Autoantibodies against p53 are associated with chromosome 17p deletions in chronic lymphocytic leukemia
Messmer, Bradley T.
Nour-Omid, Talia S.
Ghia, Emanuela
Sanchez, Ana B.
Kipps, Thomas J.
LEUKEMIA RESEARCH, 2011, 35 (07) : 965 - 967
[24] Ibrutinib rash in a patient with 17p del chronic lymphocytic leukemia
Mannis, Gabriel
Wu, Davina
Dea, Tiffany
Mauro, Theodora
Hsu, Gerald
AMERICAN JOURNAL OF HEMATOLOGY, 2015, 90 (02) : 179 - 179
[25] Allogeneic hematopoietic cell transplantation for chronic lymphocytic leukemia (CLL) with 17p deletion: A retrospective EBMT analysis
Schetelig, Johannes
van Biezen, Anja
Caballero, Dolores
Rodrigo, Martino
Remes, Kari
Garcia-Marco, Jose A.
Volin, Liisa
Perez-Simon, Jose A.
Schmitz, Norbert
Schwerdtfeger, Rainer
Ganser, Arnold
Soligo, Davide
Mohr, Brigitte
Stilgenbauer, Stephan
Brand, Ronald
Ehninger, Gerhard
de Witte, Theo
Dreger, Peter
BLOOD, 2007, 110 (11) : 22A - 23A
[26] 17p Deletion is associated with resistance of B-cell chronic lymphocytic leukemia cells to in vitro fludarabine-induced apoptosis
Turgut, Burhan
Vural, Ozden
Pala, Funda S.
Pamuk, Gulsum E.
Tabakcioglu, Kiymet
Demir, Muzaffer
Ongoren, Seniz
Soysal, Teoman
Algunes, Cetin
LEUKEMIA & LYMPHOMA, 2007, 48 (02) : 311 - 320
[27] A COMPARATIVE STUDY ON THE EFFECTS OF NUTLIN-3A IN B-CLL CHRONIC LYMPHOCYTIC LEUKEMIA CELLS WITH AND WITHOUT 17P DELETION
Reiter, M.
Schnabl, S.
Hilgarth, M.
Ponath, E.
Hubmann, R.
Demirtas, D.
Zielinski, C.
Jaeger, U.
Shehata, M.
HAEMATOLOGICA, 2016, 101 : 431 - 431
[28] TREATMENT AND 17P DELETION TESTING PATTERNS IN COMMUNITY PRACTICE FOR PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) IN THE UNITED STATES
Kapustyan, T.
Keim, H.
Meissner, B.
Zhang, L.
Jiang, D.
HAEMATOLOGICA, 2017, 102 : 420 - 420
[29] Treatment patterns and best response in a contemporary cohort of patients with relapsed/refractory chronic lymphocytic leukemia with 17p deletion
Lamanna, Nicole
Hurst, Deborah
Latremouille-Viau, Dominick
Ionescu-Ittu, Raluca
Guerin, Annie
Yim, Yeun Mi
Reyes, Carolina
LEUKEMIA & LYMPHOMA, 2015, 56 : 147 - 148
[30] Efficacy and Safety of Ibrutinib in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Leukemia with 17p Deletion: Results from the Phase II RESONATE™-17 Trial
O'Brien, Susan
Jones, Jeffrey A.
Coutre, Steven
Mato, Anthony R.
Hillmen, Peter
Tam, Constantine
Osterborg, Anders
Siddiqi, Tanya
Thirman, Michael J.
Furman, Richard R.
Ilhan, Osman
Keating, Michael
Call, Timothy G.
Brown, Jennifer R.
Stevens-Brogan, Michelle
Li, Yunfeng
Fardis, Maria
Clow, Fong
James, Danelle F.
Chu, Alvina D.
Hallek, Michael
Stilgenbauer, Stephan
BLOOD, 2014, 124 (21)

← 1 2 3 4 5 →